Hold the applause: Big Pharma has little to brag about regarding 2016 R&D productivity
Exondys 51 stands out for more reasons than its unique and controversial status as the only Duchenne muscular dystrophy drug to make it through the regulatory gamut this year.
It was one of only three new drugs approved by the FDA in the last quarter, bringing the agency’s annual tally year-to-date to a mere 17. By this time last year, the agency had OK’d a roster of 28 new drugs, on its way to a generational high of 45 for the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
